Nuclear hormone receptor targeted virtual screening

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 3045-3059

  Schapira, Matthieu ^a   Abagyan, Ruben ^a   Totrov, Maxim ^a  

^a MOLSOFT LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; CELL NUCLEUS HORMONE RECEPTOR; CELL NUCLEUS RECEPTOR; COMPOUND 21B; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR; FLUTAMIDE; GENISTEIN; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR; ISOPROTEIN; LG 121071; LIGAND; MEDROXYPROGESTERONE ACETATE; METRIBOLONE; MOXESTROL; NILUTAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; RECEPTOR ISOFORM; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TETRAHYDROCANNABINOL; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ARTICLE; CHEMICAL LIBRARY; COMPUTER MODEL; CONFORMATION; CROSS REACTION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; HOMOLOGY MODEL; LIBRARY; LIGAND BINDING DOMAIN; MODEL; PREDICTION; PROTEIN DOMAIN; PROTEIN FAMILY; QUALITY CONTROL; VIRTUAL LIBRARY SCREENING; VIRTUAL REALITY;

CRYSTALLOGRAPHY, X-RAY; HORMONE ANTAGONISTS; LIGANDS; MODELS, MOLECULAR; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0038798604     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300173     Document Type: Article

References (64)

1. Walters, P.; Stahl, M. T.; Murcko, M. A. Virtual screening an overview. Drug Discovery Today 1998, 3, 160-178.
2. Muegge, I.; Rarey, M. Small Molecule Docking and Scoring. Rev. Comput. Chem. 2001, 17, 1-60.
3. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
4. Ewing, T. A.; Kuntz, I. D. Critical evaluation of search algorithms for automated docking and database screening. J. Comput. Chem. 1997, 18, 1175-1189.
5. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
6. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
7. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 18, 1639-1662.
8. Totrov, M.; Abagyan, R. Protein-ligand docking as an energy optimization problem. Drug-Receptor Thermodynamics: Introduction and Applications; Raffa, R. B., Ed.; John Wiley & Sons: New York, 2001; pp 603-624.
9. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins 2002, 47, 409-443.
10. Boehm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
11. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
12. Totrov, M.; Abagyan, R. Derivation of Sensitive Discrimination Potential for Virtual Ligand Screening. In RECOMB '99: Proceedings of the Third Annual International Conference on Computational Molecular Biology, Lyon, France, April 11-14, 1999; Istrail, S., Pevzner, P., Waterman, M., Eds.; Association for Computing Machinery: New York, 1999.
13. Abagyan, R.; Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375-382.
14. Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G.; Pang, Y. P. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 2000, 43, 401-408.
15. Schapira, M.; Raaka, B. M.; Samuels, H. H.; Abagyan, R. Rational discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1008-1013.
16. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; Stallings, W. C.; Connolly, D. T.; Shoichet, B. K. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002, 45, 2213-2221.
17. Filikov, A. V.; Mohan, V.; Vickers, T. A.; Griffey, R. H.; Cook, P. D.; Abagyan, R. A.; James, T. L. Identification of Ligands for HIV-1 TAR RNA via Structure-Based Virtual Screening J. Comput.-Aided Drug Des. 2000, 14, 593-610.
18. Chen, Y. Z.; Zhi, D. G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43, 217-226.
19. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
20. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759-4767.
21. Stahl, M.; Rarey, M. Detailed Analysis of Scoring Functions for Virtual Screening. J. Med. Chem. 2001, 44, 1035-1042.
22. Ribeiro, R. C.; Kushner, P. J.; Baxter, J. D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 1995, 46, 443-453.
23. Dees, E. C.; Kennedym, M. J. Recent advances in systemic therapy for breast cancer. Curr. Opin. Oncol. 1998, 10, 517-522.
24. Olefsky, J. M.; Saltiel, A. R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 2000, 11, 362-368.
25. Kolvenbag, G. J.; Iversen, P.; Newling, D. W. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001, 58 (2, Suppl. 1), 16-23.
26. Wong, S. F. Oral bexarotene in the treatment of cutaneous T-cell lymphoma. Ann. Pharmacother. 2001, 35, 1056-1065.
27. Repa, J. J.; Mangelsdorf, D. J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000, 16, 459-481.
28. Brown, A. J. Mechanisms for the selective actions of vitamin D analogues. Curr. Pharm. Des. 2000, 6, 701-716.
29. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
30. Moras, D.; Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 1998, 10, 384-391.
31. Weatherman, R. V.; Fletterick, R. J.; Scanlanm, T. S. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 1999, 68, 559-581.
32. Bourguet, W.; Germain, P.; Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 2000, 21, 381-388.
33. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A.-G.; Engstrom, O.; Ljunggren, J.; Gustaffson, J.-A.; Carlquist, M. Structure of the Ligand-Binding Domain of Oestrogen Receptor Beta in the Presence of a Partial Agonist and a Full Antagonist. EMBO J. 1999, 18, 4608-4618.
34. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E,; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002, 415, 813-817.
35. ICM 2.8 Manual, Molsoft LLC: San Diego, CA; www. molsoft.com.
36. Matias, P. M.; Donner, P.; Coelho, R.; Thomaz, M.; Peixoto, C.; Macedo, S.; Otto, N.; Joschko, S.; Scholz, P.; Wegg, A.; Basler, S.; Schafer, M.; Egner, U.; Carrondo, M. A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 2000, 275, 26164-26171.
37. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R., Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909.
38. Brinkmann, A. O.; Trapman, J. Prostate cancer schemes for androgen escape. Nat. Med. 2000, 6, 628-629.
39. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000, 6, 703-706.
40. Shiau, A. K.; Barstad, D.; Radek, J. T.; Meyers, M. J.; Nettles, K. W.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A.; Agard, D. A.; Greene, G. L. Structural Characterization of a Subtype-Selective Ligand Reveals a Novel Mode of Estrogen Receptor Antagonism. Nat. Struct. Biol. 2002, 9, 359-364.
41. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
42. Maggiolini, M.; Donze, O.; Jeanninm, E.; Andom, S.; Picard, D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res. 1999, 59, 4864-4869.
43. Nogueira, C. R.; Brentanim, M. M. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 1996, 59, 271-279.
44. Gregoraszczuk, E. L. Is thyroid hormone a modulator of estrogen receptor in porcine follicular cells? Endocr. Regul. 2000, 34, 151-155.
45. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001, 292, 2329-2333.
46. Willson, T. M.; Kliewer, S. A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discovery 2002, 1, 259-66.
47. Williams, S. P.; Sigler, P. B.; Atomic structure of progesterone complexed with its receptor. Nature 1998, 393, 392-396.
48. Selman, P. J.; Wolfswinkel, J.; Mol, J. A. Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. Steroids 1996, 61, 133-137.
49. Gampe, R. T., Jr; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5, 545-555.
50. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T.; Mckee, D. D.; Moore, J. T.; Willson, T. M. Structural Determinants of Ligand Binding Selectivity between the Peroxisome Proliferator-Activated Receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924.
51. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M.; Kliewer, S. A.; Milburn, M. V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 1999, 3, 397-403.
52. Tagnon, H. J. Antiestrogens in treatment of breast cancer Cancer 1977, 39, 2959-2964.
53. Egea, P. F.; Mitschler, A.; Rochel, N.; Ruff, M.; Chambon, P.; Moras, D. Crystal Structure of the Human Rxr Alpha Ligand-Binding Domain Bound to Its Natural Ligand: 9-Cis Retinoic Acid. EMBO J. 2000, 19, 2592-2601.
54. Klaholz, B. P.; Mitschler, A.; Moras, D. Structural Basis for Isotype Selectivity of the Human Retinoic Acid Nuclear Receptor. J. Mol. Biol. 2000, 302, 155-170.
55. Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W. R.; Pfahl, M.; Lee, M. O.; Shroot, B.; Pfahl, M. J. Med. Chem. 1995, 38, 3368-3383.
56. Sun, S. Y.; Yue, P.; Dawson, M. I.; Shroot, B.; Miche, I. S.; Lamph, W. W.; Heyman, R. A.; Teng, M.; Chandraratna, R. A.; Shudo, K.; Hong, W. K.; Lotan, R. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997, 57, 4931-4939.
57. Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R. Structure and Specificity of Nuclear Receptor: Coactivator Interactions. Genes Dev. 1998, 12, 3343-3356.
58. Schoonjans, K.; Martin, G.; Staels, B.; Auwerx, J. Peroxisome proliferator-activated receptors, orphans with ligands and functions Curr. Opin. Lipidol. 1997, 8, 159-166.
59. Ness, G. C. Thyroid hormone. Basis for its hypocholesterolemic effect. J. Fla. Med. Assoc. 1991, 78, 383-385.
60. Rochel, N.; Wurtz, J. M.; Mitschler, A.; Klaholz, B.; Moras, D. The Crystal Structure of the Nuclear Receptor for Vitamin D Bound to Its Natural Ligand. Mol. Cell 2000, 5, 173-179.
61. Boehm, M. F.; Fitzgerald, P.; Zou, A.; Elgort, M. G.; Bischoff, E. D.; Mere, L.; Mais, D. E.; Bissonnette, R. P.; Heyman, R. A.; Nadzan, A. M.; Reichman, M.; Allegretto, E. A. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol. 1999, 6, 265-267.
62. Verstuyf, A.; Verlinden, L.; van Etten, E.; Shi, L.; Wu, Y.; D'Halleweyn, C.; Van Haver, D.; Zhu, G. D.; Chen, Y. J.; Zhou, X.; Haussler, M. R.; De Clercq, P.; Vandewalle, M.; Van Baelen, H.; Mathieu, C.; Bouillon, R. Biological activity of CD-ring modified 1alpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues J. Bone Miner. Res. 2000, 15, 237-252.
63. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins, 1997, Suppl. 1, 215-220.
64. Totrov, M.; Abagyan, R. Rapid boundary element solvation electrostatics calculations in folding simulations: successful folding of a 23-residue peptide. Biopolymers 2001, 60, 124-133.